61 completed, 15 unknown, 9 recruiting, 6 not yet recruiting. 38 Phase 2, 19 Not applicable, 18 Phase 3, 5 Phase 4, 2 Phase 1.
Follow Pulmonary Tuberculosis: new trials by email Literature Review of Pulmonary Tuberculosis trials Research Report on Pulmonary Tuberculosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT Pyrazinamide and Hydroxychloroquine (AI-Optimised), Standard RIPE Regimen (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol) - Pulmonary Tuberculosis | Phase 2 | Not yet recruiting | Ministry of Health, Saudi Arabia | 200 | 2026-09-01 | 2026-03-12 |
| Effectiveness of Psychosocial Counseling in Patients With a New Tuberculosis Diagnosis psychosocial counseling - Pulmonary Tuberculosis, Treatment Adherence | Not applicable | Not yet recruiting | Universitas Diponegoro | 108 | 2026-08-19 | 2026-07-14 |
| Channa Striata and Curcuma Domestica Supplementation in Patients With Active Pulmonary Tuberculosis CHANA STRIATA AND CURCUMA, Maltodextrin (Placebo) - Pulmonary Tuberculosis | Not applicable | Recruiting | DINA KEUMALA SARI | 80 | 2026-08-01 | 2026-10-21 |
| Effect of Vitamin D and Zinc Supplementation on Inflammatory Biomarkers in Pulmonary Tuberculosis Patients Vitamin D (Cholecalciferol ), Zinc (zinc sulphate) - Pulmonary Tuberculosis | Not applicable | Completed | Hasanuddin University | 32 | 2026-06-03 | 2026-10-27 |
| Artificial Intelligence-driven Tuberculosis Landscape Analysis & Stratification Research Pulmonary Tuberculosis, Tuberculosis (TB) | Not yet recruiting | Huashan Hospital | 31600 | 2026-06-01 | 2026-05-28 | |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort BLMZ - Rifampicin Resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Beijing Chest Hospital | 120 | 2025-12-01 | 2025-12-08 |
| Ultra-Short Regimen for Elderly DS-TB Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Not yet recruiting | Shenzhen Third People's Hospital | 300 | 2025-07-25 | 2025-07-22 |
| A PAN-USR TB Multi-Center Trial Bedaquiline (B), Sitafloxacin (S), Linezolid (L) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Shenzhen Third People's Hospital | 610 | 2025-06-18 | 2025-12-01 |
| Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study COPD, Interstitial Pneumonia | Not yet recruiting | Zhejiang University | 250 | 2025-04-22 | 2025-04-22 | |
| Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis Isoniazid, Rifampicin, Pyrazinamide - Pulmonary Tuberculosis | Phase 2 | Suspended | National Institute of Allergy and Infectious Diseases (NIAID) | 341 | 2025-03-11 | 2026-11-02 |
| I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis Investigational Drug, Placebo - Pulmonary Tuberculosis, Hypoalbuminemia | Not applicable | Active not recruiting | Hasanuddin University | 112 | 2024-12-17 | 2025-09-22 |
| Vitamin D3 and Monocyte Responses in Pregnant Women With Pulmonary Tuberculosis Vitamin D3 (Cholecalciferol), Standard First-Line Anti-Tuberculosis Treatment - Pulmonary Tuberculosis, Pregnancy | Not applicable | Completed | Universitas Indonesia | 32 | 2024-12-01 | 2026-10-30 |
| Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort bedaquiline, delamanid, linezolid - Drug-resistant Tuberculosis, Pulmonary Tuberculosis | Phase 3 | Active not recruiting | Huashan Hospital | 120 | 2024-11-27 | 2025-09-02 |
| Virtual Reality Cave vs. Simulated Home for Community Nursing Education: A Crossover Trial Comparing Student Competence, Confidence, and Satisfaction VR CAVE Immersive Simulation for Community Health Nursing Education, Traditional Simulated Home Environment for Community Health Nursing Training - Community Health Nursing Education, Chronic Obstructive Pulmonary Disease | Not applicable | Completed | The University of Hong Kong | 150 | 2024-08-01 | 2026-05-19 |
| Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system - Lung Cancer, Lung Infection | Recruiting | ChromX Health | 10000 | 2024-06-30 | 2025-03-26 | |
| The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB) BDL regimen - Pulmonary Tuberculosis | Phase 4 | Unknown | Beijing Chest Hospital | 45 | 2024-06-01 | 2024-06-26 |
| Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB Ganfeborole, BTZ-043, Bedaquiline (B) - Pulmonary Tuberculosis | Phase 2 | Recruiting | University College, London | 2500 | 2024-01-09 | 2026-10-15 |
| ATORvastatin in Pulmonary TUBerculosis Atorvastatin 20mg, Atorvastatin 40mg, Atorvastatin 60mg - Pulmonary Tuberculosis, Tuberculosis | Phase 2 | Recruiting | Obafemi Awolowo University Teaching Hospital | 440 | 2024-01-03 | 2025-09-25 |
| Short Course Regimen in Low Risk Active Tuberculosis- a Multicenter, Randomized, Active-controlled, Trial 4-month regimen (2HERZ/2HRE), 6-month (2HERZ/4HRE) - Pulmonary Tuberculosis | Phase 3 | Recruiting | Kaohsiung Veterans General Hospital. | 270 | 2024-01-01 | 2026-08-03 |
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort Bedaquiline, Delamanid, Contezolid - Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis | Phase 3 | Active not recruiting | Beijing Chest Hospital | 186 | 2023-12-22 | 2025-04-01 |
Showing 20 of 100. Sign in to see all of them.
Tuberculosis, Pulmonary (100) · Tuberculosis (32) · Tuberculosis, Multidrug-Resistant (8) · Bronchiectasis (3) · COVID-19 (3) · Extensively Drug-Resistant Tuberculosis (3) · Lung Neoplasms (3) · Pulmonary Disease, Chronic Obstructive (3) · Cystic Fibrosis (2) · Diabetes Mellitus, Type 2 (2) · HIV Infections (2) · Lung Diseases, Interstitial (2) · Tuberculosis, Extrapulmonary (2) · Acute-Phase Reaction (1) · Alagille Syndrome (1)
Actinomycetales Infections (100) · Bacterial Infections (100) · Bacterial Infections and Mycoses (100) · Respiratory Tract Diseases (100) · Respiratory Tract Infections (100) · Gram-Positive Bacterial Infections (99) · Infections (99) · Lung Diseases (99) · Mycobacterium Infections (99) · Tuberculosis (68) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · RNA Virus Infections (5) · Virus Diseases (5) · Digestive System Diseases (4)
Isoniazid (23) · Pyrazinamide (21) · Ethambutol (20) · Rifampin (20) · bedaquiline (16) · pretomanid (14) · Linezolid (12) · Moxifloxacin (12) · OPC-67683 (7) · Protons (5) · Cholecalciferol (4) · Clofazimine (4) · delpazolid (4) · PNU-100480 (3) · 2-(2-methyl-1,4-dioxa-8-azaspiro(4.5)dec-8-yl)-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (2)
Global Alliance for TB Drug Development (10) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Access to Advanced Health Institute (AAHI) (3) · Beijing Chest Hospital (3) · Centers for Disease Control and Prevention (2) · Gates Medical Research Institute (2) · Hasanuddin University (2) · Huashan Hospital (2) · LigaChem Biosciences, Inc. (2) · Michael Hoelscher (2) · National University Hospital, Singapore (2) · Shenzhen Third People's Hospital (2) · TASK Applied Science (2) · Taipei Medical University WanFang Hospital (2) · Allama Iqbal Open University Islamabad (1)
South Africa (30) · China (15) · Uganda (9) · India (8) · Tanzania (7) · Indonesia (6) · Brazil (5) · Philippines (5) · Taiwan (5) · United States (5) · Mexico (4) · Peru (4) · South Korea (4) · Vietnam (4) · Canada (3)
Andreas Diacon, MD (3) · Rodney Dawson, MD (3) · Andreas Diacon (2) · Clifton E Barry, Ph.D. (2) · Morounfolu Olugbosi, MD (2) · Nicholas Paton (2) · A K Jain, MBBS FICA (1) · Adreas Diacon (1) · Alexander Pym, MB BMRCP PhD (1) · Ali Zumla, BSc MBChB MSc PhD (1) · Alice M Muller, MD (1) · Amina Jindani, MD (1) · Aminuddin Aminuddin, MD, Ph.D, Sp.GK (1) · Anatoly I Saulin, Master (1)
PMID 36808186, PMID 17705950, PMID 18173355, PMID 18245055, PMID 19424460, PMID 20174642, PMID 20610636, PMID 21215445, PMID 22430968, PMID 22828481, PMID 22850121, PMID 23075177, PMID 23150149, PMID 23590701, PMID 25196020, PMID 25363329, PMID 25489785, PMID 25622149, PMID 25795076, PMID 25863562, PMID 26038418, PMID 26095067, PMID 26104205, PMID 26394045, PMID 26847437, PMID 28504996, PMID 29528048, PMID 29595510, PMID 29779774, PMID 29973153, PMID 30210819, PMID 31988102, PMID 32130813, PMID 32381098, PMID 33229425, PMID 33306991, PMID 33374006, PMID 33951066, PMID 34252302, PMID 34489274, PMID 34604901, PMID 34871098, PMID 35131835, PMID 35366820, PMID 35636648, PMID 36053506, PMID 36455068, PMID 36546625, PMID 36804834, PMID 36966799
U01AI134585 (1)